Latest Information Update: 07 Dec 2006
At a glance
- Originator Dana-Farber Cancer Institute; Shionogi
- Class Antineoplastics
- Mechanism of Action Alkylating agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 12 Apr 1999 Preclinical development for Cancer in USA (Unknown route)